The generic name of Scapho is secukinumab, which is an injectable medicine and the first interleukin-17A (IL-17A) inhibitor to be approved in India.
Novartis Waiting for Regulators Approval to Market Its New Heart Failure Drug in Europe
Once European Commission approves Entresto, it will be available for the treatment of adult patients with symptomatic chronic reduced ejection fraction (HFrEF).
Once European Commission approves Entresto, it will be available for the treatment of adult patients with symptomatic chronic reduced ejection fraction (HFrEF).
‘Novartis Healthcare has launched the drug, Scapho in India for the treatment of moderate-to-severe plaque psoriasis in adult patients.’
The generic name of Scapho is secukinumab, which is an injectable medicine and the first interleukin-17A (IL-17A) inhibitor to be approved in India for the treatment of moderate-to-severe plaque psoriasis in adult patients. The company has launched the drug in the strength of 15mg in India, but it is already available in the US and Europe under the brand name Cosentyx.
“This approval marks a significant milestone in the treatment of psoriasis, providing a new and important first-line biologic treatment option for patients who are candidates for systemic therapy,” Novartis said in a statement.
Novartis' Oxytocin Nasal Spray can Help Men Reduce Calorie Intake
A new study has revealed that Novartis' oxytocin nasal spray, a synthetic nasal formulation of the love hormone, can help men eat fewer calories.
A new study has revealed that Novartis' oxytocin nasal spray, a synthetic nasal formulation of the love hormone, can help men eat fewer calories.
Novartis Acquires Rights to GSK's Ofatumumab Drug For Multiple Sclerosis Treatment
The Swiss pharma will handle the worldwide development and commercialization of the drug - Ofatumumab - for use in multiple sclerosis, sources said.
The Swiss pharma will handle the worldwide development and commercialization of the drug - Ofatumumab - for use in multiple sclerosis, sources said.
Swiss Drug Firm Collaborates With Amgen to Develop Treatments for Alzheimer's Disease
Novartis and California-based biotech company Amgen will jointly develop neuroscience treatments for illnesses like Alzheimer's disease and migraine headaches.
Novartis and California-based biotech company Amgen will jointly develop neuroscience treatments for illnesses like Alzheimer's disease and migraine headaches.
